ARAV News and Press, Aravive Inc. From 11/02/22

More Short Squeeze Penny Stocks For Your November Watch List If you want to make money with penny stocks, learning how to find them and what to look for is a great first step. This article looks at a phenomenon known as a short squeeze. In this scenario, traders will bet against stocks ...

Short Squeeze Penny Stocks In Focus Do you want to make money with penny stocks but might be looking for alternative methods to stay ahead of the curve? The “secret” is in the data. Making money in the stock market isn’t as complicated as you might think as long as ...

Aravive ( NASDAQ: ARAV ) announced Tuesday a direct stock offering of 45.18 million shares and accompanying warrants in the private placement deal with biotech investors. The units are issued at $0.9199 each with half of warrant exercisable at $0.7949 per share through exp...

HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) (“Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced that it has entered into definitive agreements with new biotechnology investors, ...

HOUSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines I...

HOUSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer wi...

HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer wi...

Aravive press release ( NASDAQ: ARAV ): Q2 GAAP EPS of -$0.61 (vs. -$0.35 Y/Y) misses by $0.02 . Revenue of $1.6M (-57.8% Y/Y) beats by $0.67M . For further details see: Aravive Q2 GAAP EPS misses, revenue beats

Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and Phase 1b Pancreatic Adenocarcinoma Data. Presented Updated Clinical Data at ASCO Showing Continued Best-In-Class Potential of Batiraxcept i...

Aravive ( NASDAQ: ARAV ) has announced the appointment of Dr. Robert B. Geller as Chief Medical Officer . Dr. Geller will play a critical role in progressing Aravive’s portfolio of programs in ovarian, renal and pancreatic cancers. For further details see...